Interleukin-2 (IL-2, Proleukin) is one of the most effective agents in the treatment of metastatic renal cell carcinoma and metastatic melanoma. High-dose IL-2 therapy produces overall response rates of 15% to 20%;
ONCOLOGY Vol 16 No 11_Suppl_13
Although high-dose interleukin-2 (IL-2, Proleukin), a highly toxic agent used in the treatment of renal cell carcinoma and melanoma, was initially associated with treatment-related mortality, it can, in the appropriate
Advertisement
Advertisement
Trending on CancerNetwork
1
KRd-Based Quadruplets May “Eliminate” Transplant Need for Multiple Myeloma
2
KRd Appears to Exhibit Greater Outcomes in Standard-Risk Multiple Myeloma
3
Creating a “Watershed Moment” for Novel Therapeutic Access in Lymphoma
4
ADCE-D01 Earns FDA Fast Track Designation in Soft Tissue Sarcoma
5
